Covid19 Clinical Trial
Official title:
Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events
An estimated 22% of the global population is at an increased risk of a severe form of
COVID-19, while one in four coronavirus patients admitted to intensive care unit will develop
a pulmonary embolism. A major public health question remains to be investigated: why COVID-19
is mild for some, critically severe for others and why only a percentage of COVID-19 patients
develop thrombosis, despite the disease's proven hypercoagulable state? Patients' intrinsic
characteristics might be responsible for the deep variety of disease forms.
Our study aims to assess the validity of the hypothesis according to which underlining
genetic variations might be responsible for different degrees of severity and thrombotic
events risks in the novel coronavirus disease.
Moreover, we suspect that prothrombotic genotypes occuring in the genes that encode
angiotensin-converting enzyme (ACE-DEL/INS) and angiotensinogen (AGT M235T) are involved in
the unpredictable evolution of COVID-19, both in terms of severity and thrombotic events, due
to the strong interactions of SARS-CoV-2 with the renin-angiotensin-aldosterone system
(RAAS). Therefore, we also aim to assess the validity of the theory according to which there
is a pre-existing atypical modulation of RAAS in COVID-19 patients that develop severe forms
and/or thrombosis.
Our hypothesis is based on various observations. Firstly, there is a substantial similarity
with a reasonably related condition such as sepsis, for which there is a validated theory
stating that thrombophilic mutations affect patients' clinical response. Secondly, racial and
ethnic genetic differences are responsible for significant dissimilar thrombotic risks among
various nations. Thirdly, an increase in stroke incidence has been reported in young patients
with COVID-19, without essential thrombosis risk factors, favoring the idea that a genetic
predisposition could contribute to increase the thrombotic and thromboembolic risk. Fourthly,
the plasminogen activator inhibitor (PAI)-1 4G/5G inherited mutation was found to be
responsible for a thrombotic state causing post-SARS osteonecrosis.
The study's protocol will cover the following steps:
• Collected data from COVID-19 patients at admission will include:
- Descriptive general demographic data
- Previous pathologies and thrombosis risk factors
- Routine biological data (the blood routinely collected will also be used for SARS-Cov-2
specific RT-PCR exam)
Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to
assess the presence of prothrombotic genotypes:
- Factor V Leiden
- Factor V 4070 A G (Hr2)
- Factor II G20210A
- Methylenetetrahydrofolate reductase (MTHFR) C677T
- MTHFR A1298C
- Cystathionine β-synthase (CBS) 844ins68
- PAI-1 4G/5G
- Glycoprotein IIIa T1565C (HPA-1a/b)
- ACE-DEL/INS
- Apolipoprotein E (ApoE)
- AGT M235T
- Angiotensin II type 1 receptor (ATR-1) A1166C
- Fibrinogen - 455 G A
- Factor XIII Val34Leu SpO2, respiratory rate, PaO2/FiO2 RAAS components
- Imagistic procedures (chest X-ray or CT)
- All patients with a positive SARS-CoV-2 PCR test will be included
- Patients will be divided into three groups depending on disease severity and
the presence of thrombotic state:
- 1st group includes COVID-19 patients with proved
- venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis
occurring in more atypical places such as in the veins of the brain, liver, kidney,
mesenteric vein and the veins of the arms)
- or arterial thrombosis (heart attacks, strokes)
- 2nd group encompasses asymptomatic patients and those with mild or moderate
disease, according to current guidelines, without thrombosis: no symptoms or
evidence of lower respiratory disease by clinical assessment or imaging and a SpO2
≥ 94%
- 3rd group includes severe disease, according to current guidelines, without
thrombosis: respiratory frequency > 30 breaths per minute, SpO2 < 94%, PaO2/FiO2 <
300 mmHg, or lung infiltrates >50%
- Statistical methods will be employed to check for significant differences
between prothrombotic mutations frequency and RAAS components levels for the
three groups
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |